Squarepoint Ops LLC Invests $193,000 in Vigil Neuroscience, Inc. (NASDAQ:VIGL)

Squarepoint Ops LLC bought a new stake in shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 113,596 shares of the company's stock, valued at approximately $193,000. Squarepoint Ops LLC owned 0.28% of Vigil Neuroscience as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of VIGL. Cubist Systematic Strategies LLC raised its stake in Vigil Neuroscience by 53.0% during the 4th quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company's stock worth $41,000 after buying an additional 8,358 shares during the period. Jane Street Group LLC bought a new position in shares of Vigil Neuroscience in the 4th quarter worth $83,000. Barclays PLC grew its position in Vigil Neuroscience by 43.6% in the 4th quarter. Barclays PLC now owns 64,049 shares of the company's stock valued at $109,000 after purchasing an additional 19,436 shares during the period. Northern Trust Corp increased its stake in Vigil Neuroscience by 29.0% during the 4th quarter. Northern Trust Corp now owns 64,737 shares of the company's stock valued at $110,000 after purchasing an additional 14,572 shares in the last quarter. Finally, Two Sigma Advisers LP raised its holdings in Vigil Neuroscience by 243.8% during the fourth quarter. Two Sigma Advisers LP now owns 69,100 shares of the company's stock worth $117,000 after buying an additional 49,000 shares during the last quarter. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages recently issued reports on VIGL. JMP Securities reiterated a "market perform" rating on shares of Vigil Neuroscience in a report on Thursday, May 22nd. Citigroup lowered shares of Vigil Neuroscience to a "market perform" rating in a research report on Thursday, May 22nd. Citizens Jmp downgraded shares of Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 22nd. Jefferies Financial Group lowered Vigil Neuroscience to a "hold" rating in a report on Thursday, May 22nd. Finally, HC Wainwright cut Vigil Neuroscience from a "buy" rating to a "neutral" rating and dropped their price objective for the stock from $14.00 to $8.00 in a report on Tuesday, May 27th. Ten investment analysts have rated the stock with a hold rating, According to data from MarketBeat.com, Vigil Neuroscience currently has an average rating of "Hold" and a consensus target price of $10.80.

Vigil Neuroscience Stock Up 0.1%

Shares of Vigil Neuroscience stock traded up $0.01 on Thursday, reaching $7.87. The company's stock had a trading volume of 3,583,095 shares, compared to its average volume of 703,991. The company has a market capitalization of $367.31 million, a price-to-earnings ratio of -3.82 and a beta of 3.43. The firm's fifty day simple moving average is $3.78 and its two-hundred day simple moving average is $2.71. Vigil Neuroscience, Inc. has a 52 week low of $1.31 and a 52 week high of $7.95.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.04. As a group, research analysts predict that Vigil Neuroscience, Inc. will post -2.07 EPS for the current year.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.